GT201300036A - Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos - Google Patents
Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismosInfo
- Publication number
- GT201300036A GT201300036A GT201300036A GT201300036A GT201300036A GT 201300036 A GT201300036 A GT 201300036A GT 201300036 A GT201300036 A GT 201300036A GT 201300036 A GT201300036 A GT 201300036A GT 201300036 A GT201300036 A GT 201300036A
- Authority
- GT
- Guatemala
- Prior art keywords
- n3pglu
- amiloide
- peptidic
- same
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS QUE SELECTIVAMENTE UNEN PÉPTIDO BETA AMILOIDE N3PGLU Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADA A PÉPTIDO BETA AMILOIDE POR LO QUE SON DE UTILIDAD EN UN NÚMERO DE CONDICIONES Y ENFERMEDADES, QUE INCLUYEN LA ENFERMEDAD DE ALZHEIMER, ANGIOPATÍA AMILOIDE CEREBRAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37302610P | 2010-08-12 | 2010-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201300036A true GT201300036A (es) | 2014-07-16 |
Family
ID=44543826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201300036A GT201300036A (es) | 2010-08-12 | 2013-02-08 | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8679498B2 (es) |
| EP (3) | EP2603523B1 (es) |
| JP (2) | JP5980207B2 (es) |
| KR (1) | KR101498833B1 (es) |
| CN (2) | CN105111308B (es) |
| AU (1) | AU2011289629B2 (es) |
| BR (1) | BR112013004056B8 (es) |
| CA (1) | CA2805114C (es) |
| CL (1) | CL2013000390A1 (es) |
| CO (1) | CO6670526A2 (es) |
| CR (1) | CR20130016A (es) |
| CY (2) | CY1120144T1 (es) |
| DK (3) | DK3339323T3 (es) |
| DO (1) | DOP2013000029A (es) |
| EA (1) | EA023021B1 (es) |
| EC (1) | ECSP13012436A (es) |
| ES (3) | ES2564252T3 (es) |
| GT (1) | GT201300036A (es) |
| HK (1) | HK1180703A1 (es) |
| HR (3) | HRP20160151T1 (es) |
| HU (2) | HUE028678T2 (es) |
| IL (2) | IL224030B (es) |
| LT (2) | LT3042917T (es) |
| MA (1) | MA34461B1 (es) |
| ME (3) | ME03661B (es) |
| MX (2) | MX342782B (es) |
| MY (2) | MY163521A (es) |
| NO (1) | NO3042917T3 (es) |
| NZ (2) | NZ626665A (es) |
| PE (1) | PE20130817A1 (es) |
| PL (3) | PL3339323T3 (es) |
| PT (2) | PT3339323T (es) |
| RS (3) | RS59652B1 (es) |
| SG (2) | SG10201509330XA (es) |
| SI (3) | SI3339323T1 (es) |
| UA (1) | UA107600C2 (es) |
| WO (1) | WO2012021469A1 (es) |
| ZA (1) | ZA201300437B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| LT3042917T (lt) * | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
| US20170008955A1 (en) * | 2014-02-03 | 2017-01-12 | Cnj Holdings, Inc. | Humanized beta-amyloid binding molecules and uses thereof |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| AU2015287227B2 (en) | 2014-07-10 | 2021-02-18 | Universitat Zurich | Immune-stimulating monoclonal antibodies against human interleukin-2 |
| TWI599358B (zh) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JP2018501482A (ja) | 2014-12-19 | 2018-01-18 | プロビオドルグ エージー | ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| CN108290951B (zh) * | 2015-09-23 | 2022-04-01 | 瑞泽恩制药公司 | 优化抗cd3双特异性抗体和其用途 |
| IL260218B2 (en) | 2016-01-11 | 2023-04-01 | Novartis Ag | Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins |
| JOP20170004B1 (ar) * | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| AR107783A1 (es) | 2016-03-15 | 2018-06-06 | Lilly Co Eli | Terapia de combinación |
| TW201740954A (zh) * | 2016-03-16 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| CN109641052A (zh) * | 2016-08-18 | 2019-04-16 | 伊莱利利公司 | BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法 |
| TWI669119B (zh) | 2016-10-21 | 2019-08-21 | 美國禮來大藥廠 | 組合療法 |
| EP3532064B1 (en) | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| CA3041595A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| TW201827467A (zh) * | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| SG11202001281WA (en) | 2017-08-22 | 2020-03-30 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| SG11202005361RA (en) | 2017-12-14 | 2020-07-29 | H Lundbeck As | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| US20220177560A1 (en) | 2019-03-26 | 2022-06-09 | Janssen Pharmaceutica Nv | Antibodies to Pyroglutamate Amyloid-B and Uses Thereof |
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| US20230250193A1 (en) * | 2020-06-17 | 2023-08-10 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
| IL301572A (en) | 2020-10-02 | 2023-05-01 | Lilly Co Eli | Methods for reducing the protein content of the host cell in protein purification processes |
| JP2024503025A (ja) | 2021-01-11 | 2024-01-24 | イーライ リリー アンド カンパニー | 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| IL312045A (en) | 2021-10-22 | 2024-06-01 | Lilly Co Eli | Combination therapy with O-GLCNACASE (OGA) inhibitors. |
| IL312380A (en) | 2021-10-29 | 2024-06-01 | Lilly Co Eli | Compounds and methods targeting interleukin-34 |
| WO2023076970A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| WO2023076971A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| AU2022379194A1 (en) | 2021-10-29 | 2024-05-02 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| WO2023150483A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
| WO2024020470A1 (en) | 2022-07-21 | 2024-01-25 | Eli Lilly And Company | PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| WO2005018424A2 (en) * | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| WO2005025616A1 (ja) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | 抗体の用途 |
| ES2375627T3 (es) * | 2004-02-23 | 2012-03-02 | Eli Lilly And Company | Anticuerpos anti-abeta. |
| EP2298807A3 (en) * | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| PL2046833T3 (pl) | 2006-07-14 | 2014-01-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
| RU2523894C2 (ru) * | 2007-04-18 | 2014-07-27 | Янссен Альцгеймер Иммунотерапи | Предупреждение и лечение церебральной амилоидной ангиопатии |
| US20110092436A1 (en) | 2008-06-12 | 2011-04-21 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| CA2730073A1 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
| JP5828762B2 (ja) * | 2008-07-21 | 2015-12-09 | プロビオドルグ エージー | 診断用抗体アッセイ |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| LT3042917T (lt) * | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
-
2011
- 2011-08-09 LT LTEP15196358.4T patent/LT3042917T/lt unknown
- 2011-08-09 MA MA35653A patent/MA34461B1/fr unknown
- 2011-08-09 HU HUE11745672A patent/HUE028678T2/en unknown
- 2011-08-09 MX MX2013001716A patent/MX342782B/es active IP Right Grant
- 2011-08-09 EA EA201270813A patent/EA023021B1/ru not_active IP Right Cessation
- 2011-08-09 ME MEP-2019-356A patent/ME03661B/me unknown
- 2011-08-09 DK DK18150424.2T patent/DK3339323T3/da active
- 2011-08-09 RS RS20191581A patent/RS59652B1/sr unknown
- 2011-08-09 RS RS20160129A patent/RS54685B1/en unknown
- 2011-08-09 PT PT181504242T patent/PT3339323T/pt unknown
- 2011-08-09 HU HUE15196358A patent/HUE037524T2/hu unknown
- 2011-08-09 KR KR1020137003412A patent/KR101498833B1/ko active IP Right Grant
- 2011-08-09 BR BR112013004056A patent/BR112013004056B8/pt active IP Right Grant
- 2011-08-09 NO NO15196358A patent/NO3042917T3/no unknown
- 2011-08-09 PL PL18150424T patent/PL3339323T3/pl unknown
- 2011-08-09 JP JP2013524156A patent/JP5980207B2/ja active Active
- 2011-08-09 NZ NZ626665A patent/NZ626665A/en unknown
- 2011-08-09 SG SG10201509330XA patent/SG10201509330XA/en unknown
- 2011-08-09 US US13/810,895 patent/US8679498B2/en active Active
- 2011-08-09 EP EP11745672.3A patent/EP2603523B1/en active Active
- 2011-08-09 SI SI201131817T patent/SI3339323T1/sl unknown
- 2011-08-09 ME MEP-2016-28A patent/ME02352B/me unknown
- 2011-08-09 WO PCT/US2011/046994 patent/WO2012021469A1/en active Application Filing
- 2011-08-09 NZ NZ606095A patent/NZ606095A/en unknown
- 2011-08-09 ME MEP-2018-79A patent/ME03032B/me unknown
- 2011-08-09 PT PT151963584T patent/PT3042917T/pt unknown
- 2011-08-09 PL PL15196358T patent/PL3042917T3/pl unknown
- 2011-08-09 PE PE2013000253A patent/PE20130817A1/es active IP Right Grant
- 2011-08-09 MY MYPI2013700226A patent/MY163521A/en unknown
- 2011-08-09 EP EP18150424.2A patent/EP3339323B1/en active Active
- 2011-08-09 EP EP15196358.4A patent/EP3042917B1/en active Active
- 2011-08-09 DK DK11745672.3T patent/DK2603523T3/en active
- 2011-08-09 ES ES11745672.3T patent/ES2564252T3/es active Active
- 2011-08-09 ES ES15196358.4T patent/ES2664128T3/es active Active
- 2011-08-09 SI SI201131449T patent/SI3042917T1/en unknown
- 2011-08-09 AU AU2011289629A patent/AU2011289629B2/en active Active
- 2011-08-09 DK DK15196358.4T patent/DK3042917T3/en active
- 2011-08-09 MY MYPI2016001651A patent/MY181969A/en unknown
- 2011-08-09 RS RS20180323A patent/RS57026B1/sr unknown
- 2011-08-09 LT LTEP18150424.2T patent/LT3339323T/lt unknown
- 2011-08-09 CA CA2805114A patent/CA2805114C/en active Active
- 2011-08-09 CN CN201510613319.6A patent/CN105111308B/zh active Active
- 2011-08-09 CN CN201180039876.1A patent/CN103068848B/zh active Active
- 2011-08-09 SG SG2013005210A patent/SG187586A1/en unknown
- 2011-08-09 SI SI201130740T patent/SI2603523T1/sl unknown
- 2011-08-09 ES ES18150424T patent/ES2764728T3/es active Active
- 2011-08-09 PL PL11745672T patent/PL2603523T3/pl unknown
- 2011-09-08 UA UAA201301508A patent/UA107600C2/ru unknown
-
2012
- 2012-12-31 IL IL224030A patent/IL224030B/en unknown
-
2013
- 2013-01-16 CR CR20130016A patent/CR20130016A/es unknown
- 2013-01-16 ZA ZA2013/00437A patent/ZA201300437B/en unknown
- 2013-02-05 DO DO2013000029A patent/DOP2013000029A/es unknown
- 2013-02-08 CL CL2013000390A patent/CL2013000390A1/es unknown
- 2013-02-08 EC ECSP13012436 patent/ECSP13012436A/es unknown
- 2013-02-08 GT GT201300036A patent/GT201300036A/es unknown
- 2013-02-12 CO CO13028596A patent/CO6670526A2/es unknown
- 2013-02-12 MX MX2016005533A patent/MX355268B/es unknown
- 2013-07-11 HK HK13108135.4A patent/HK1180703A1/zh unknown
- 2013-09-27 US US14/039,113 patent/US8961972B2/en active Active
-
2016
- 2016-02-10 HR HRP20160151TT patent/HRP20160151T1/hr unknown
- 2016-04-22 JP JP2016086317A patent/JP6395755B2/ja active Active
-
2018
- 2018-04-18 HR HRP20180616TT patent/HRP20180616T1/hr unknown
- 2018-04-20 CY CY20181100420T patent/CY1120144T1/el unknown
-
2019
- 2019-12-12 HR HRP20192233TT patent/HRP20192233T1/hr unknown
-
2020
- 2020-01-07 CY CY20201100005T patent/CY1122458T1/el unknown
-
2021
- 2021-07-29 IL IL285226A patent/IL285226B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201300036A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| GT201700033A (es) | Anticuerpos anti tigit | |
| ECSP19020740A (es) | Anticuerpos anti-cd27 | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| CO2017012974A2 (es) | Anticuerpos de unión a tau | |
| AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
| AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
| SV2017005486A (es) | Anticuerpos a tau y usos de los mismos | |
| GT200600240A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
| CY1122987T1 (el) | Αντισωματα εναντι αμυλοειδους βητα | |
| UY33202A (es) | Proteínas de unión a cd127 | |
| CL2019001043A1 (es) | Anticuerpos anti-il-33 y usos de los mismos. | |
| ECSP13012609A (es) | Composición farmacéutica | |
| UY34988A (es) | Anticuerpos humanos para gfr alfa 3 y métodos para su uso | |
| CL2012002896A1 (es) | Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva. | |
| AR083044A1 (es) | Anticuerpos anti-cd48 y usos de los mismos | |
| CO2017012971A2 (es) | Anticuerpos de unión a tau | |
| UY32812A (es) | Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana. | |
| CO2017000346A2 (es) | Anticuerpos de unión a protofibrillas aβ | |
| DOP2012000232A (es) | Proteínas de unión a antigeno especificas para el componente amiloide serico p | |
| AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| BR112015003957A2 (pt) | alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria | |
| CL2015001520A1 (es) | Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares |